Literature DB >> 10353405

Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change nephrotic syndrome.

B S Cho1, S R Yoon, J Y Jang, K H Pyun, C E Lee.   

Abstract

Although the pathogenesis of childhood minimal change nephrotic syndrome (MCNS) has not been clearly defined, the current hypothesis favors an involvement of T cell dysfunction. The symptom onset and the relapse of MCNS are frequently associated with allergy and increased IgE levels in sera. Since a T cell-derived cytokine interleukin-4 (IL-4) plays a key role in the regulation of IgE production and allergic response, we investigated the role of IL-4 in the pathophysiology of MCNS. Using fluorescence-activated cell scanning we observed a significantly higher expression of CD23, the type II IgE receptor (FcepsilonRII), on fresh B cells from active MCNS patients (n=22) compared with age-matched healthy normal controls (n=12). The upregulation of CD23 correlates with greater IL-4 activity in the culture supernatant of MCNS peripheral blood lymphocytes (PBLs) than normal PBLs stimulated by mitogens, as assessed by the CD23-inducing effect of the PBL supernatant on tonsillar B cells. Furthermore, Northern blot and reverse transcription-based polymerase chain reaction analysis have revealed significantly elevated levels of IL-4 mRNAs both in mitogen-stimulated and unstimulated MCNS PBLs, compared with healthy normals or disease controls with other renal disorders. Together these results strongly suggest that the upregulation of IL-4 in T cells may be part of the T cell dysfunction involved in MCNS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353405     DOI: 10.1007/s004670050592

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  31 in total

1.  T regulatory cell function in idiopathic minimal lesion nephrotic syndrome.

Authors:  Carlos Araya; Leila Diaz; Clive Wasserfall; Mark Atkinson; Wei Mu; Richard Johnson; Eduardo Garin
Journal:  Pediatr Nephrol       Date:  2009-06-03       Impact factor: 3.714

2.  Risk of idiopathic nephrotic syndrome among children with asthma: a nationwide, population-based cohort study.

Authors:  Chang-Ching Wei; Cheng-Li Lin; Te-Chun Shen; Yu-Fen Li
Journal:  Pediatr Res       Date:  2015-04-30       Impact factor: 3.756

Review 3.  Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.

Authors:  Kazunari Kaneko; Shoji Tsuji; Takahisa Kimata; Tetsuya Kitao; Sohsaku Yamanouchi; Shogo Kato
Journal:  World J Pediatr       Date:  2015-01-28       Impact factor: 2.764

Review 4.  Regulatory T cells and minimal change nephropathy: in the midst of a complex network.

Authors:  R Bertelli; A Bonanni; A Di Donato; M Cioni; P Ravani; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2015-10-12       Impact factor: 4.330

5.  Correlation Between Idiopathic Nephrotic Syndrome and Atopy in Children - Short Review.

Authors:  Elena Camelia Berghea; Mihaela Balgradean; Ionela-Loredana Popa
Journal:  Maedica (Bucur)       Date:  2017-01

6.  Implication of serum IgE in childhood nephrotic syndrome.

Authors:  You-Lin Tain; Tsung-Yi Chen; Kuender D Yang
Journal:  Pediatr Nephrol       Date:  2003-10-31       Impact factor: 3.714

Review 7.  Minimal change nephropathy and focal segmental glomerulosclerosis.

Authors:  Peter W Mathieson
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

8.  Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.

Authors:  Xiao-Ling Niu; Sheng Hao; Ping Wang; Wei Zhang; Gui-Mei Guo; Ying Wu; Xin-Yu Kuang; Guang-Hua Zhu; Wen-Yan Huang
Journal:  Biomed Rep       Date:  2016-06-30

Review 9.  The pediatric nephrotic syndrome spectrum: clinical homogeneity and molecular heterogeneity.

Authors:  Asher D Schachter
Journal:  Pediatr Transplant       Date:  2004-08

10.  Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

Authors:  Koichi Kamei; Shuichi Ito; Kandai Nozu; Shuichiro Fujinaga; Makiko Nakayama; Mayumi Sako; Mari Saito; Maki Yoneko; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-05-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.